期刊档案 · Advances in Cell and Gene Therapy

Advances in Cell and Gene Therapy

ISSN 2573-8461 · John Wiley & Sons, Inc. · USA

Advances in Cell and Gene Therapy 完全开放获取,APC 约 840 美元,出版商公布投稿到接收约 100 天,录用比例约 23%(社区反馈),2025 年发文 4 篇。

影响因子—暂无公布值
中科院分区—未被分区表收录
CiteScore 分区—暂无 CiteScore 排名
审稿周期100 天出版商公布的投稿到接收时间
版面费840 USD完全开放获取
录用比例23%投稿社区平均反馈
年发文量4 篇2025 年 · OpenAlex 统计

研究范围

研究范围与定位

Advances in Cell and Gene Therapy 由 John Wiley & Sons, Inc. 出版。按 OpenAlex 近年发文统计,该刊主要发表 CAR-T cell therapy research、Hematopoietic Stem Cell Transplantation、Immunotherapy and Immune Responses 等主题的论文,这 3 个主题约占 35.7%,主导子领域为 Hematology。(根据 OpenAlex 主题统计与中科院分区数据生成)

Advances in Cell and Gene Therapy is an international journal publishing original, high-quality, peer-reviewed articles which cover basic and clinical research relating to advances in cell, gene, and immune therapies and their use in the treatment of a wide range of diseases, including cancer, genetic and immune diseases, and others. The topics the journal covers include cell, gene and immune therapies in children and adults with a wide range of disorders, including cancers, genetic and immune diseases, and others. All articles include a section or feature detailing the current and future clinical implications of the research. Among the extensive and provocative reviews, Advances in Cell and Gene Therapy provides a forum for presenting original research articles and sharing ideas for innovation, as well as disseminating knowledge of primary clinical relevance to advance patient care.

摘自期刊官网 Aims & Scope

研究方向(LetPub):Advances in Cell and Gene Therapy

主编 Carol Miao出版商官网

编委会国家分布:未见中国大陆编委;主要国家 美国 3、中国香港 1、印度 1(共 5 位编委标注了国家) 编委会 ↗出版商官网 ·

主要研究主题 OpenAlex 近年发文统计,占比为近似值

  1. CAR-T cell therapy researchMedicine14.5%
  2. Hematopoietic Stem Cell TransplantationMedicine14.1%
  3. Immunotherapy and Immune ResponsesImmunology and Microbiology7.1%
  4. Virus-based gene therapy researchBiochemistry, Genetics and Molecular Biology7.1%
  5. Acute Myeloid Leukemia ResearchMedicine6.2%
  6. Lymphoma Diagnosis and TreatmentMedicine5.4%
  7. T-cell and B-cell ImmunologyImmunology and Microbiology4.6%
  8. Multiple Myeloma Research and TreatmentsMedicine4.6%

分区与收录

学科分区与数据库收录

中科院期刊分区表

期刊分区表( 2025年3月升级版)未收录

该期刊未被此版本分区表收录。

《新锐期刊分区表》( 2026年3月发布)未收录

该期刊未被此版本分区表收录。

期刊分区表( 2023年12月旧的升级版)未收录

该期刊未被此版本分区表收录。

数据库收录

收录数据库:暂无记录。

国际期刊预警名单:各版本均未列入LetPub

不同版本、大类与小类分别展示,不将不同评价口径合并为一个分区值;投稿与考核前请确认所在机构采用的版本。

指标

影响力指标与发文规模

影响力指标

h-index
12OpenAlex ·
i10-index
18OpenAlex ·
两年平均被引
1OpenAlex ·
Gold OA 文章占比
0%LetPub ·

发文规模

年发文量(出版商公布) 2025
3出版商官网 ·
年下载量(出版商公布) 2025
22,184出版商官网 ·

逐年发文量 OpenAlex 统计 · 累计 135 篇 · 当年数据不完整

年份发文量其中 OA被引
20260063
202543105
202422112
202366102
202264143
2021126109

不同来源的统计口径与观测时间不同,页面保留各来源原值;“出版商公布”为期刊官网自述数据。

审稿与录用

审稿周期与录用情况

文章统计的审稿周期 Crossref 登记的稿件日期 · 至

样本不足近 24 个月只有 3 篇文章登记了投稿与接收日期,不足以给出中位数

只统计最终被录用并发表的文章,不含被拒稿件的处理时间,因此通常长于出版商公布的"首次决定时间"。

各来源数据

平均审稿速度(社区反馈)
期刊官网数据:平均Submission to first decision (median): 43 days;网友分享经验:LetPub ·
平均录用比例(社区反馈)
23%LetPub ·
录用率(出版商公布) 2025
23%出版商官网 ·
投稿到首次决定 2025
43 天出版商官网 ·
投稿到接收 2025
100 天出版商官网 ·
接收到发表 2025
22 天出版商官网 ·
评审方式
单盲同行评审出版商官网

社区反馈来自投稿者样本,置信度 0.5,不代表期刊承诺;“出版商公布”的时间节点定义以官网为准。

费用与开放获取

版面费与开放获取政策

完全开放获取LetPub

所有文章开放获取,通常向作者收取文章处理费(APC)。

来源文章处理费费用减免许可证观测时间
OpenAlexUSD 840 / EUR 720 / GBP 620——
出版商官网有,金额未公布——

费用以期刊官网为准;不同来源的观测时间可能不同,页面保留各来源原值,不做平均。

投稿要求

文章类型与投稿政策(官网)

接收的文章类型4 种
  1. editorialAdvances in Cell and Gene Therapy publishes the following types of submissions: Original Research Review Article Editorial Letter to the Editor未说明篇幅
  2. letter to the editorAdvances in Cell and Gene Therapy publishes the following types of submissions: Original Research Review Article Editorial Letter to the Editor未说明篇幅
  3. original researchAdvances in Cell and Gene Therapy publishes the following types of submissions: Original Research Review Article Editorial Letter to the Editor未说明篇幅
  4. review articleAdvances in Cell and Gene Therapy publishes the following types of submissions: Original Research Review Article Editorial Letter to the Editor未说明篇幅
出版商官网
官网政策摘录AI 使用、作者资格、利益冲突、数据可用性、出版伦理、许可与版权、开放获取、同行评审、预印本、自存档、试验注册 / 报告规范
AI 使用 Disclosing the use of artificial intelligence (AI)

If you or your co-authors have used Artificial Intelligence Generated Content (AIGC) tools such as ChatGPT and others based on large language models (LLMs) to develop any portion of a manuscript, their use must be described transparently and in detail in the Methods section. Find more details on Wiley’s AI guidelines for researchers and Wiley’s AI policy in full in the Best Practices Guidelines on…

原文 ↗出版商官网 ·
作者资格 Authorship

Author name change policy: Wiley updates and republishes. 模型摘要

All listed authors should have contributed to the manuscript substantially and have agreed to the final submitted version. You can review the Authorship section of Wiley’s Best Practice Guidelines on Research Integrity and Publishing Ethics for Wiley’s definition of authorship.

原文 ↗出版商官网 ·
利益冲突 Conflicts of Interest (COIs)

A common reason for third-party complaints of published articles is an allegation that author(s) have not fully disclosed perceived conflicts of interest (COIs). Such complaints may lead to ethics investigations by the journal and publisher. Therefore, when submitting your manuscript, you should disclose any potential conflicts of interests (also referred to as “competing interests”) that might ap…

原文 ↗出版商官网 ·
数据可用性 Data Sharing

Data availability statement required. 模型摘要

This journal encourages data sharing. You can learn more about data sharing in Wiley’s Data Sharing Policies resource.

原文 ↗出版商官网 ·
出版伦理 COPE

This journal adheres to the ethical standards set by the Committee on Publication Ethics (COPE) to uphold integrity in scholarly research and publishing. While COPE previously organized its guidance around "core practices," these have since been replaced with a topic-based structure to better reflect the evolving needs of the research community. You can learn more about this transition and explore…

原文 ↗出版商官网 ·
许可与版权 Copyright and licensing

This is an open access journal. Authors of accepted papers pay an Article Publication Charge (APC) and their papers are published under a Creative Commons (CC) license. For more information on this journal’s APCs and licensing policy, please visit this journal’s Open Access page. Note: Some funders require authors to use a particular type of CC license. Please check directly with your funder to de…

原文 ↗出版商官网 ·
开放获取 Open access

Open access journal 模型摘要

This is an open access journal. Submissions will be subject to an Article Publication Charge (APC) if accepted and published in the journal. Please read more about APCs and whether you may be eligible for waivers or discounts through your institution, your funder, or a country waiver at Wiley Author Services.

原文 ↗出版商官网 ·
同行评审 Peer Review Model

Peer review model: single-anonymized for applicable article types. 模型摘要

We follow a single-anonymized peer review model, for applicable article types. Except where otherwise stated, manuscripts are peer reviewed by at least one anonymous reviewer and an Associate or Assistant Editor. Papers authored by Editors or Editorial Board members of the journal will be sent to Editors unaffiliated with the author or institution and monitored carefully to ensure there is no peer…

原文 ↗出版商官网 ·
预印本 Preprint Policy

Preprint policy: accepts preprint-published articles. 模型摘要

The journal accepts articles previously published on preprint servers and does not consider this to compromise the novelty of the results. Articles based on content previously made public only on a preprint server, institutional repository, or in a thesis will be considered. The preprint should be cited. You will be asked to update any pre-publication versions with a link to the final published ar…

原文 ↗出版商官网 ·
自存档 Self-Archiving definitions and policies

Self-archiving allowed under specific conditions. 模型摘要

This journal’s standard copyright agreement allows for self-archiving of different versions of the article under specific conditions. You can learn more by reading Wiley’s self-archiving policy.

原文 ↗出版商官网 ·
试验注册 / 报告规范 Reporting guidelines

Authors are strongly encouraged to use appropriate reporting guidelines when preparing and submitting manuscripts, to maximize transparency and reproducibility. Our editors and reviewers are also encouraged to use them in the review process. Completed checklists should be provided in the supplementary files on submission. We particularly encourage the use of: Wiley Biological and Biomedical Scienc…

原文 ↗出版商官网 ·

摘录来自期刊官网页面,仅保留原文片段;“模型摘要”由 Workers AI 生成并经原文校验,以官网为准。

基本信息

出版信息与官方入口

出版商
John Wiley & Sons, Inc.
出版国家或地区
USA
出版语言
English
ISSN
2573-8461
官方链接

常见问题

关于 Advances in Cell and Gene Therapy 的常见问题

Advances in Cell and Gene Therapy 的审稿周期多长?

出版商公布的投稿到接收时间约为 100 天,平均录用比例反馈为“23%”;期刊官网公布的录用率为 23%(2025)。文章统计只含被录用的稿件,出版商数据口径以官网为准,社区反馈来自投稿者样本,均不代表期刊承诺。

Advances in Cell and Gene Therapy 的编委会里有中国学者吗?

期刊官网编委会页面上标注了国家的 5 位编委中,没有中国大陆学者;人数最多的国家是 美国(3 位)、中国香港(1 位)、印度(1 位)。统计按编委会页面列出的机构国家计,仅供参考。

Advances in Cell and Gene Therapy 是开放获取期刊吗?版面费多少?

Advances in Cell and Gene Therapy 为完全开放获取。APC 约 840 美元。

来源与更新

本页事实来自 LetPub、出版商官网、OpenAlex;每个数字旁标注来源与观测日期,冲突数据保留各来源原值。LetPub 原始详情页:查看 ↗(2026-08-26 归档)。最近更新:。